Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted

Description

In this Product Explainer Geriatrician A/Prof Michael Woodward AM explains an adjuvanted vaccine indicated for the active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).1

Reference: 1. AREXVY Product Information

This video was developed by Heathed with funding from GSK.
Views of the speaker are their own and do not necessarily reflect that of GSK. GSK recommends usage in accordance with the Product Information.

PM-AU-RSA-WCNT-240007 Date of approval: March 2024.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Peter Wong

Prof Peter Wong

Fracture Prevention and Osteoporosis Management After Menopause

Dr Richard Symes

Dr Richard Symes

Ophthalmology Update: New Treatments for Old Conditions

Clinical A/Prof Carolyn Allan

Clinical A/Prof Carolyn Allan

Testosterone for Men – Common Myths and Recent Development

Dr Victoria Hayes

Dr Victoria Hayes

Conversation Strategies for Unfunded Vaccinations

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

A/Prof Michael Woodward AM

expert

A/Prof Michael Woodward AM

Geriatrician; Head of Aged Care and Memory Clinic, Austin Health

Date published: 9 March 2024